MRK vs SLB: Which Is the Better Buy?
Side-by-side comparison of Merck & Co., Inc. and SLB N.V. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-06-20.
Merck & Co., Inc. · Healthcare
$113.87
-12.1% upside to fair value
Grade D
High Quality
VS
SLB N.V. · Energy
$48.09
-33.4% upside to fair value
Grade C
QuantHub Verdict
MRK has more upside to fair value
(-12.1%).
SLB trades at a lower forward P/E
(21.8x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
MRK |
SLB |
| Current Price |
$113.87 |
$48.09 |
| Fair Value Estimate |
$100.14 |
$32.01 |
| Upside to Fair Value |
-12.1%
|
-33.4%
|
| Market Cap |
$281.2B |
$71.9B |
| Forward P/E |
32.0x
|
21.8x
|
| EV / EBITDA |
17.3x
|
10.9x
|
| Price / Sales |
4.3x
|
2.0x
|
| Price / FCF |
19.9x
|
15.4x
|
| Revenue Growth YoY |
+4.3%
|
+2.7%
|
| Gross Margin |
75.9%
|
17.3%
|
| Operating Margin |
27.6%
|
14.4%
|
| Return on Equity |
17.9%
|
13.5%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
5.02%
|
6.51%
|
| Analyst Consensus |
Hold
|
Strong Buy
|
Investment Thesis
Merck & Co., Inc. is a leading global healthcare company specializing in pharmaceuticals, vaccines, and animal health products. Its business quality is high, supported by a durable competitive moat anchored in the dominant global position of Keytruda in PD-1/PD-L1 oncology, a strong vaccines portfolio including Gardasil, and scale in R&D and manufacturing. The company benefits from a seasoned lea…
SLB N.V. is a global leader in oilfield services, specializing in well construction, production systems, reservoir performance, and digital solutions. The company benefits from a durable competitive moat anchored in technology, integrated service breadth, and global infrastructure, with a management team that has long tenure and deep industry experience. Despite solid free cash flow generation of…
Accumulation Zones
| Metric |
MRK |
SLB |
| Zone Low |
$75.11 |
$24.01 |
| Zone High |
$85.12 |
$27.21 |
| In Buy Zone? |
No
|
No
|